(Date:12/2/2008)...ewswire/ -- Ingenious Med (IM) welcomes new CEO, S...in inpatient practice,management solutions, with ...,software, revenue management, medical services, ...e-year CEO, Dr. Steven Liu, is confident Williford...nt in all sectors, as he steps into,the role. Liu...
(Date:12/2/2008)... who took it in first 3 months more likely to have...ealthDay News) -- Infants whose mothers take folic...increased risk for respiratory illness, according ...o reduce the risk of birth defects, and many count... researchers examined data on more than 32,000 chi...
(Date:12/2/2008)...earchers at The University of Nottingham has ident...er. , The research, published in the journal Pr...A and funded by a 72,000 grant from the British Lu...r gene, LIMD1, is responsible for protecting the b...r possible new treatments and early screening tech...
(Date:12/2/2008)...cs, Inc., a privately held biopharmaceutical compa...s evaluating its lead investigational product cand...1, a novel, proprietary fixed-dose combination pro...ated a statistically significant reduction in the ...(NSAID)-induced upper gastrointestinal (gastric an...
Breaking Medicine News(10 mins):Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Gene which protects against lung cancer identified 2Health News:Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints 2(Date:12/1/2008)...irl with Hypophosphatasia Treated With ENB-0040 at...nnipeg , , MONTREAL, Dec. 1 ...ny focused on developing novel therapeutics for se...st infant patient in its clinical program for hypo...zyme Replacement Therapy (ERT) with ENB-0040 for t...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
(Date:12/1/2008)...A, Dec. 1 GeoVax Labs, I...biotechnology company developing,human vaccines f...y Virus) and,other infectious agents, announced t...e Trials will take place in twelve sites across No... in collaboration with The National Institutes of,...
(Date:11/30/2008)...O, Dec. 1 Abnormalities...ted in children with autism spectrum disorder by u...study presented today at the annual meeting of the... , "Using MEG, we can record the tiny magneti...," said Timothy Roberts, Ph.D., vice chair of rese...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Disability payments may spur drug abuse 14 1Disability payments may spur drug abuse 14 2MRI finds breast cancer before it becomes dangerous 9 1MRI finds breast cancer before it becomes dangerous 9 2MRI finds breast cancer before it becomes dangerous 9 3Survival differences by race most apparent in advanced stages of breast cancer 4 1Survival differences by race most apparent in advanced stages of breast cancer 4 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long Term Results 96 1New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long Term Results 96 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long Term Results 96 3...AACR, SAN DIEGO, April 17 /PRNewswire-FirstCall/ -... an in vitro study showing,that the active metabol...diated anti-tumor response by inducing cytokine se...ibody-dependent cellular,cytotoxicity (ADCC), duri...the American Association of Cancer Research (AACR)...
...tCall/ - Oncolytics,Biotech Inc. ("Oncolytics") an.... of , New York, entitled "In Vivo Synergy between... Human HCT116,Xenografts" is scheduled to be prese...Research (AACR) Annual Meeting in Los,Angeles, CA....searchers found that treatment of human colon canc...
Other Medicine Technology:Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 2Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 3...ginal Vibratome Semi-Automatic Tissue Sectioning S...d tissue sectioning system. Researchers from aroun...sic for their fresh and fresh fixed tissue section...Automatic Tissue Sectioning Systems, the biologica...
...ratome 1000 Plus Sectioning System provides a vers...or plant tissues. The 1000 employs a vibrating bl...zing or embedding. The creation of artifacts, the...me activities, and other deleterious effects inher...
The Vibratome comes standard with a square vice mounting device. These specimen blocks are utilized for mounting specimens and placing in the Vibratome holding vice. The blocks are annodized black
This is a perfect tool for retrieving free floating sections from the Vibratome bath.
Medicine Products: